Latest / The Bear Market Podcast with Fexingo: Surviving Downturns, Buying the Dip, and Long-Term Resilience / GLP-1 Weight-Loss Drugs Are a Hidden Corporate Balance Sheet Risk
Transcript
- Lucas: So, Bank of America's CEO just said the bank is spending a quarter of a billion dollars a year on weight-loss drugs for its employees. That's two hundred and fifty million dollars — on GLP-1s — as a line item in their cost structure. Luna: Two hundred fifty million. I mean, that's not nothing. That's like a mid-sized company's entire annual profit. Lucas: Exactly. And it got me thinking about something we've touched on before but never drilled into: the GLP-1 story isn't just a pharma or a consumer story anymore. It's becoming a corporate cost story. And I don't think the market has fully priced that in. Luna: So before we dig into the numbers, I've got to say — if you're finding value in these conversations, and you want to keep this show free of ads and paywalls, you can support us at buy me a coffee dot com slash fexingo. It's a small gesture that keeps us going. Lucas: Yeah, genuinely appreciate anyone who chips in. It helps us keep doing the research and having these real talks. So — back to the bank's pharmacy bill. Two hundred fifty million. Let's put that in context with what we're seeing in the broader market right now. Lucas: Look, the S&P 500 is up four percent in the last five days. The Nasdaq is up over five. The VIX is down to just under sixteen. It feels like calm waters. But underneath that, companies are dealing with structural cost increases that have nothing to do with interest rates or the Fed. Luna: Right. And GLP-1s are a perfect example. Because unlike, say, a spike in commodity prices, this is a cost that's not going away. It's building every year. Lucas: Bank of America isn't unique. We're seeing large employers across the board — in finance, retail, manufacturing — reporting that GLP-1 coverage is one of their fastest-growing healthcare expenses. And the drug costs are steep. List prices for these medications can run over a thousand dollars a month. Luna: So if you've got, say, ten thousand employees on these drugs, that's potentially a hundred million plus a year just on the pharma bill. Lucas: Exactly. And that's before you account for the fact that many patients stay on these drugs long-term — this isn't a six-month treatment. It's a chronic medication for a lot of people. Luna: So what does that do to a company's margins? I mean, if you're looking at a firm like a restaurant chain where labor is already a huge chunk of costs, adding a pharmacy rider like that has to hurt. Lucas: It does. And here's the thing — most investors look at healthcare costs as a percentage of revenue, and for most companies it's still small. But in absolute dollar terms, it's becoming meaningful. And the trajectory is what worries me. The adoption rate is climbing every quarter. Luna: And it's not just the direct drug cost, right? There's also the administrative cost, the counseling, the monitoring. It all adds up. Lucas: Right. And the insurance side is getting complicated too. Some insurers are starting to push back — asking for prior authorizations, step therapy, things like that. But employers are under pressure to offer GLP-1 coverage because it's become a recruiting and retention tool. Luna: So it's almost like a new form of compensation. You can't attract top talent if your benefits package doesn't include these drugs. Lucas: And that's the trap. It becomes a competitive necessity, so you can't just cut it. But you also can't pass the full cost onto employees easily, because then it defeats the purpose. Luna: I remember reading that some self-insured employers are starting to exclude GLP-1s from their plans. But that seems like a short-term fix that could backfire. Lucas: It's a delicate balance. Some companies are trying to manage costs by negotiating directly with drugmakers, or switching formularies. But the list prices keep going up. Luna: So if I'm an investor, how do I actually figure out which companies are exposed? I mean, you can't just look at the income statement and see 'GLP-1 expense'. Lucas: You can't. But you can look at a few tells. First, check the healthcare cost trend in the footnotes — some companies disclose their total medical claims or their per-employee healthcare cost. Second, look at the employee demographics. A younger workforce is probably less exposed than an older one. Third, check the industry — you'll see more exposure in white-collar, higher-income sectors where benefits are richer. Luna: And also, just listening to earnings calls. CEOs are starting to mention GLP-1 costs in their prepared remarks. Bank of America's CEO just did. Lucas: And that's a tell. When a CEO voluntarily brings up a cost line, it means it's material enough to address. And it's not just B of A. We're hearing it from a broader set of companies, from logistics to health insurers. Luna: So what's the market's view? Is this fully priced in? I'd argue no, because the adoption curve is still accelerating. Lucas: I think you're right. And it's a slow burn. It's not like a one-quarter shock. It's a creeping cost that could shave a few basis points off margins every year for the next decade. That's the kind of thing that compounds. Luna: And the market hates creeping costs that are hard to model. Because they usually show up when you least expect them — like in a recession, when revenues are already under pressure. Lucas: And that's the real risk. We looked at the GDP data today — real growth is running at one point five percent annualized, down from over two percent. The economy is cooling. If we get a downturn, that two hundred fifty million dollars for B of A is going to feel a lot heavier when revenue is shrinking. Luna: So the conversation about GLP-1s is really a conversation about cost structure resilience. The companies that can adapt — maybe by managing utilization, or negotiating better deals — will come out ahead. Lucas: Yes. And there's also an opportunity angle. The drugmakers themselves are obviously the direct beneficiaries. Eli Lilly and Novo Nordisk are printing money. But also, the companies that provide the clinics, the telehealth platforms, the data analytics for managing these patients — they're all part of that ecosystem. Luna: But for the average investor, the takeaway is: pay attention to your holdings' healthcare costs, especially if they're in labor-intensive industries. It's a silent margin killer. Lucas: And it's a reminder that the biggest risks to a portfolio often aren't the ones on the front page. They're the slow-moving costs that quietly eat away at earnings. The VIX is low, the market's ripping, but this kind of structural expense is something you can't see in a daily chart. Luna: So as a listener, what's one concrete thing you can do? Maybe check if your own employer's healthcare costs are rising faster than revenue. That's a micro-signal for your own company. Lucas: And as an investor, next time you read an earnings call transcript, search for the words 'pharmacy' or 'healthcare costs' and see if it's mentioned. If it is, dig in. That's where the story is. Luna: Alright, so we've got the corporate angle. But what about the broader economy? If employers are spending more on healthcare, that's money not going into wages or capital investment. Lucas: Exactly. And that's a productivity story. If you're spending more on healthcare, you have less to invest in R&D or equipment. That could be one reason real GDP growth is slowing even though the market is celebrating. Luna: It's like a hidden tax on growth. And it's hitting the middle class particularly hard — because they're the ones with employer-sponsored coverage. Lucas: And again, this is the kind of topic where we could go a hundred different directions. But I think the key insight for today is that GLP-1s are no longer just a miracle drug story. They're a cost center, a competitive weapon, and a potential headwind to margins across corporate America. Luna: And it's a perfect example of how a single innovation can ripple through the entire economy in ways that aren't obvious at first. Lucas: Yeah. And I think we'll be talking about this for years. For now, it's worth watching how employers adapt — and who passes the cost onto the consumer. Luna: Well, and who benefits. If you're a small business, you might be at a disadvantage because you can't negotiate the same drug prices. But if you're a large employer, you might be able to leverage your scale. Lucas: That's a fair point. And it could widen the moat between big and small companies. Big firms can self-insure, they can negotiate, they can build wellness programs. Smaller firms are stuck with the list prices. Luna: So maybe the real bottom line is: if you're thinking about the future of corporate profits, don't just look at AI and interest rates. Look at the pharmacy bill. Lucas: That's the takeaway. And next time you see a company report a slight miss on margins, check if healthcare costs had anything to do with it. Because it's probably not the last time.